90 related articles for article (PubMed ID: 7817161)
1. Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Debruyne FM; Collins VP; van Dekken H; Jenkins RB; Klocker H; Schalken JA; Sesterhenn IA
Scand J Urol Nephrol Suppl; 1994; 162():65-71; discussion 115-27. PubMed ID: 7817161
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetics of prostate cancer.
Nupponen NN; Visakorpi T
Microsc Res Tech; 2000 Dec; 51(5):456-63. PubMed ID: 11074616
[TBL] [Abstract][Full Text] [Related]
3. Differential chromosome allelic imbalance in the progression of human prostate cancer.
Latil A; Fournier G; Cussenot O; Lidereau R
J Urol; 1996 Dec; 156(6):2079-83. PubMed ID: 8911394
[TBL] [Abstract][Full Text] [Related]
4. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer.
Jenkins R; Takahashi S; DeLacey K; Bergstralh E; Lieber M
Genes Chromosomes Cancer; 1998 Feb; 21(2):131-43. PubMed ID: 9491325
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
Latil A; Cussenot O; Fournier G; Driouch K; Lidereau R
Cancer Res; 1997 Mar; 57(6):1058-62. PubMed ID: 9067271
[TBL] [Abstract][Full Text] [Related]
7. Searching for suppressor genes in prostate cancer.
Peehl DM
Cancer Surv; 1991; 11():25-34. PubMed ID: 1668728
[TBL] [Abstract][Full Text] [Related]
8. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers.
Suzuki H; Komiya A; Emi M; Kuramochi H; Shiraishi T; Yatani R; Shimazaki J
Genes Chromosomes Cancer; 1996 Dec; 17(4):225-33. PubMed ID: 8946204
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of proximal 6q deletions in prostate cancer.
Cooney KA; Wetzel JC; Consolino CM; Wojno KJ
Cancer Res; 1996 Sep; 56(18):4150-3. PubMed ID: 8797584
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of prostate cancer.
Visakorpi T
Ann Chir Gynaecol; 1999; 88(1):11-6. PubMed ID: 10230676
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathology of prostate carcinoma. Academic playground or guide for diagnosis and therapy planning?].
Bubendorf L
Verh Dtsch Ges Pathol; 2004; 88():158-64. PubMed ID: 16892547
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer.
Latil A; Cussenot O; Fournier G; Baron JC; Lidereau R
Clin Cancer Res; 1995 Nov; 1(11):1385-9. PubMed ID: 9815935
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts.
Williams BJ; Jones E; Kozlowski JM; Vessella R; Brothman AR
Genes Chromosomes Cancer; 1997 Apr; 18(4):299-304. PubMed ID: 9087570
[TBL] [Abstract][Full Text] [Related]
16. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer.
Trybus TM; Burgess AC; Wojno KJ; Glover TW; Macoska JA
Cancer Res; 1996 May; 56(10):2263-7. PubMed ID: 8625295
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of prostate cancer.
Isaacs WB
Cancer Surv; 1995; 25():357-79. PubMed ID: 8718527
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of prostate cancer progression.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Cancer Surv; 1995; 23():19-32. PubMed ID: 7621457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
